Neoantigen × AI
Daily research signal
TRACKING / TRIAL TRACKER

NCT07551037 — Fujian Medical University Union Hospital cancer immunotherapy trial

Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy

TrackingPhase 1RecruitingRegistry updated 1 May 2026
Phase 1phaseRecruitingregistry status90enrollment2026-09-01primary completion

Registry IDNCT07551037
Lead sponsorFujian Medical University Union Hospital
Collaborators
PhasePhase 1
StatusRecruiting
IndicationAcute Myeloid Leukemia, Personalized Active Immunotherapy, Maintenance Therapy
Enrollment90 participants (target)
Start date2024-09-01
Primary completion2026-09-01 (est.)
Last registry update1 May 2026

Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07551037), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.

Daily coverage of the modality, tumor type and players this study touches:

What phase is NCT07551037?

NCT07551037 (Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy) is registered on ClinicalTrials.gov as Phase 1, sponsored by Fujian Medical University Union Hospital.

Is NCT07551037 recruiting?

As of the 2026-05-01 registry update, NCT07551037 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.

Who is running NCT07551037?

The lead sponsor is Fujian Medical University Union Hospital.

What condition does NCT07551037 study?

The registered conditions are Acute Myeloid Leukemia, Personalized Active Immunotherapy, Maintenance Therapy. Primary completion is listed as 2026-09-01 (estimated).

Are results available for NCT07551037?

neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07551037.

Back to the full neoantigen vaccine trial tracker 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.